sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.
Age ≥18 years
Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment
low density lipoprotein cholesterol > 70mg/dl (1.8mmol/L)
Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained.
Contraindications to statins
There are contraindications to MRI examination or cannot accept MRI examination
Stenosis caused by vasculitis, arterial dissection and moyamoya disease
Patients with active bleeding or obvious bleeding tendency
Parallel
PCSK9 inhibitor
DrugThe aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
Recurrent stroke
the recurrent rate of clinical stroke
Intracranial arterial
Degree of change in intracranial arterial stenosis
Plaque changes
Plaque volume and load changes
Vascular remodeling index
Vascular remodeling index changes
Adverse events
The incidence of muscle related events, allergic reactions, injection site reactions, bleeding events and other adverse events was assessed
Click on the lead sponsor to view all of their trials.
